Mid Infrared Imaging to Predict Response to Neoadjuvant Therapy in Early-Stage Breast Cancer
Project Description:
Breast cancer is the most common non-dermatological malignancy in women with an estimated 276,480 new breast cancer cases and 42,170 cancer deaths projected in 2020 in the United States. Radiographically, MRI is commonly used to assess baseline and end of treatment responses, but more frequent interval imaging with MRI or ultrasound is limited due to the high cost and limited availability. Our group has shown in preliminary studies that a Mid Infrared (MidIR) imaging (8-12μm spectral range) can detect functional changes in the tumor vicinity at the very early stages of treatment sessions (possibly even at the first/second sessions).
